Literature DB >> 23118668

Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs.

Manika Suryadevara1, Kelly E Steidl, Luke A Probst, Jana Shaw.   

Abstract

OBJECTIVES: The objective of this study was to measure the appropriateness of vancomycin monitoring in a pediatric tertiary care center and to evaluate the effectiveness of two interventions, autonomous pharmacy therapeutic drug monitoring and health care provider education, in reducing avoidable pediatric patient trauma and hospital cost.
METHODS: A retrospective chart review evaluating vancomycin therapeutic drug monitoring (TDM) in pediatric inpatients was performed before and after the introduction of an autonomous pharmacy TDM program and health care provider (HCP) education.
RESULTS: Thirty-five patients were included in our study, prior to any intervention. Of these, 9% of patients had trough concentrations appropriately deferred. Of the total of 64 trough concentrations obtained, 94% were considered to be inappropriate. After the start of the autonomous pharmacy TDM program, of the 54 eligible patients (111 troughs), 9% had trough concentrations appropriately deferred, and 34% were inappropriate. In the 3-month period following the introduction of HCP education in combination with pharmacy TDM, we identified 27 eligible patients. Among those, 15% of the patients had trough concentrations appropriately deferred. Of the 43 trough concentrations obtained, only 9% were considered to be inappropriate. The combination of pharmacy TDM with HCP education decreased annualized hospital cost by 60%, from $13,080 to $5232.
CONCLUSIONS: Inappropriate vancomycin TDM occurs commonly in our institution, resulting in unnecessary hospital cost and patient trauma. The combination of pharmacy TDM and HCP education significantly improved clinical practice; however, results were short-lived. Further interventions, such as computer based order entry, will likely be needed to reinforce and improve long-term TDM practice in pediatric patients.

Entities:  

Keywords:  antibiotic stewardship; therapeutic drug monitoring; vancomycin

Year:  2012        PMID: 23118668      PMCID: PMC3470436          DOI: 10.5863/1551-6776-17.2.159

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  18 in total

1.  Evaluating the appropriateness of digoxin level monitoring.

Authors:  F Cañas; M J Tanasijevic; N Ma'luf; D W Bates
Journal:  Arch Intern Med       Date:  1999-02-22

2.  The occurrence of high levels of acute behavioral distress in children and adolescents undergoing routine venipunctures.

Authors:  G B Humphrey; C M Boon; G F van Linden van den Heuvell; H B van de Wiel
Journal:  Pediatrics       Date:  1992-07       Impact factor: 7.124

3.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.

Authors:  Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton
Journal:  Clin Infect Dis       Date:  2006-12-13       Impact factor: 9.079

4.  Strategies for physician education in therapeutic drug monitoring.

Authors:  D W Bates; S J Soldin; P M Rainey; J N Micelli
Journal:  Clin Chem       Date:  1998-02       Impact factor: 8.327

5.  Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy.

Authors:  C A Cab Bond; Cynthia L Raehl
Journal:  Am J Health Syst Pharm       Date:  2005-08-01       Impact factor: 2.637

6.  Appropriateness of antiepileptic drug level monitoring.

Authors:  R A Schoenenberger; M J Tanasijevic; A Jha; D W Bates
Journal:  JAMA       Date:  1995 Nov 22-29       Impact factor: 56.272

7.  A prospective survey of reactions to blood tests by children and adolescents.

Authors:  C Fradet; P J McGrath; J Kay; S Adams; B Luke
Journal:  Pain       Date:  1990-01       Impact factor: 6.961

8.  Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity.

Authors:  William Darko; Joseph J Medicis; Adrienne Smith; Roy Guharoy; David E Lehmann
Journal:  Pharmacotherapy       Date:  2003-05       Impact factor: 4.705

Review 9.  Clinical implications of unmanaged needle-insertion pain and distress in children.

Authors:  Robert M Kennedy; Janet Luhmann; William T Zempsky
Journal:  Pediatrics       Date:  2008-11       Impact factor: 7.124

10.  Caregivers' responses to pain in their children in the emergency department.

Authors:  Ryan W Smith; Vibhuti Shah; Ran D Goldman; Anna Taddio
Journal:  Arch Pediatr Adolesc Med       Date:  2007-06
View more
  9 in total

1.  Vancomycin monitoring in children using bayesian estimation.

Authors:  Jennifer Le; Becky Ngu; John S Bradley; William Murray; Austin Nguyen; Lyn Nguyen; Gale L Romanowski; Tiana Vo; Edmund V Capparelli
Journal:  Ther Drug Monit       Date:  2014-08       Impact factor: 3.681

2.  Appropriateness of vancomycin therapeutic drug monitoring and its outcomes among non-dialysis patients in a tertiary hospital in Singapore.

Authors:  Jun Jie Benjamin Seng; Mei Hui Amanda Yong; Zi Xin Peh; Jie Lin Soong; Mooi Heong Tan
Journal:  Int J Clin Pharm       Date:  2018-06-12

3.  Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life.

Authors:  Tatjana Van Der Heggen; Franky M Buyle; Barbara Claus; Annemie Somers; Petra Schelstraete; Peter De Paepe; Sophie Vanhaesebrouck; Pieter A J G De Cock
Journal:  Int J Clin Pharm       Date:  2021-04-28

4.  Gap Analysis for the Conversion to Area Under the Curve Vancomycin Monitoring in a Small Rural Hospital.

Authors:  Jennifer L Cole
Journal:  Fed Pract       Date:  2020-06

5.  Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation.

Authors:  Sook Hee An; Eun Mi Lee; Jae Yeon Kim; Hye Sun Gwak
Journal:  Eur J Hosp Pharm       Date:  2019-02-20

6.  Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?

Authors:  Wesley D Kufel; Robert W Seabury; William Darko; Luke A Probst; Christopher D Miller
Journal:  Hosp Pharm       Date:  2017-03

7.  Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.

Authors:  Ree Nar Yoo; Seo Hee Kim; Jina Lee
Journal:  J Korean Med Sci       Date:  2017-01       Impact factor: 2.153

8.  Clinical Response and Hospital Costs of Therapeutic Drug Monitoring for Vancomycin in Elderly Patients.

Authors:  Yun Kim; Soohyun Kim; Jinsook Park; Howard Lee
Journal:  J Pers Med       Date:  2022-01-26

9.  Estimated Clinical and Economic Impact through Use of a Novel Blood Collection Device To Reduce Blood Culture Contamination in the Emergency Department: a Cost-Benefit Analysis.

Authors:  Erik Skoglund; Casey J Dempsey; Hua Chen; Kevin W Garey
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.